within Pharmacolibrary.Drugs.ATC.N;

model N06DX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.296 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 700 / 1000000,
    adminCount     = 1,
    Vd             = 0.00307,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Donanemab is a humanized IgG1 monoclonal antibody that targets amyloid-beta plaques in the brain. It is being developed as a disease-modifying treatment for Alzheimer's disease and is currently under regulatory review, not yet fully approved for general use as of June 2024.</p><h4>Pharmacokinetics</h4><p>Population PK results in patients with early symptomatic Alzheimer’s disease; typical demographics: both sexes, older adults.</p><h4>References</h4><ol><li><p>Lowe, SL, et al., &amp; Sims, JR (2021). Donanemab (LY3002813) Phase 1b Study in Alzheimer&#x27;s Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. <i>The journal of prevention of Alzheimer&#x27;s disease</i> 8(4) 414–424. DOI:<a href=&quot;https://doi.org/10.14283/jpad.2021.56&quot;>10.14283/jpad.2021.56</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34585215/&quot;>https://pubmed.ncbi.nlm.nih.gov/34585215</a></p></li><li><p>Xu, J, et al., &amp; Cui, Y (2025). Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study. <i>Clinical pharmacology in drug development</i> None –. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1533&quot;>10.1002/cpdd.1533</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40377397/&quot;>https://pubmed.ncbi.nlm.nih.gov/40377397</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06DX05;
